首页 > 文章详情

2024年4月份FDA批准的抗肿瘤新药、新适应证一览

04月30日

整理：研值圈

来源：研值圈

2024年4月，美国FDA共批准了8个抗肿瘤新药适应证。8个药物中，包括2个CAR-T、2个ADC、1个ALK抑制剂、一个泛RAF抑制剂、1个IL-15激动剂、1个放射性核素偶联药物。

2024年4月批准的.png

参考文献

[1]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
[2]https://www.fda.gov/media/177545/download?attachment
[3]https://www.fda.gov/media/177564/download?attachment
[4]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer
[5]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer
[6]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-pediatric-patients-12-years-and-older-gep-nets
[7]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric
[8]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer

责任编辑：Linda
排版编辑：Linda

EDC推广.jpg EDU广告.jpg